Blockchain Registration Transaction Record

Telomir Pharmaceuticals Announces Breakthrough Preclinical Data on Telomir-1 Candidate

Telomir Pharmaceuticals releases new preclinical data on Telomir-1 candidate, showcasing reversal of cellular decline. Findings support expansion into ASD and SD, with plans to engage in FDA's Rare Disease Endpoint Advancement Pilot Program.

This news matters as Telomir Pharmaceuticals' innovative approach to reversing cellular decline has significant implications for longevity and the treatment of rare diseases. The company's expansion into ASD and SD, along with engagement in the FDA's pilot program, showcases a commitment to advancing medical solutions for challenging conditions.